ClinicalTrials.gg
CompletedNCT01552863Updated Aug 31, 2015

A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers

A Phase 1 interventional study of Oxycodone and Oxycodone in Pain, sponsored by Pain Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-08-31.

Sponsored by Pain Therapeutics · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing oxycodone in Pain — 4 open to participants now, 5 under way, 1 of them phase 3. Oxycodone · Pain.

Enrollment
42nd of 50
21 · median 67
Started
2012
with 5 others
Phase 1
10 of 50
2 open now
Registered
15th of 50
by date
Lead sponsor
3 of 50
Pain Therapeutics

Among the 50 studies testing oxycodone in Pain, this one is the 42nd largest by enrollment, is one of 6 that started in 2012, is one of 10 in phase 1, and was the 15th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 50 studies testing oxycodone in Pain are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing oxycodone in Pain, or all of them as a file.
02

Study summary

This is an open-label (both the physician and healthy volunteer know which medication will be administered), single-dose, 6- dosing period study to characterize the pharmacokinetics of oxycodone (process by which oxycodone is absorbed, distributed, metabolized, and eliminated by the body). This study will consist of three parts that will take place over approximately 90 days. Part 1 of the study has 4 dosing periods, while Parts 2 and 3 have one dosing period each.

Read the detailed description

This study will estimate the PK and relative BA of oxycodone following single oral 40-mg doses of 3 modified PF-00345439 Formulations E, F, and G compared with the reference PF-00345439 Formulation A under fed conditions in healthy volunteers in order to aid in selection of a final formulation.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • pharmacokinetics
  • bioavailability
  • oxycodone.
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female subjects between 18 and 55 years of age (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of disease.
  • History of obstructive sleep apnea.
  • Positive urine drug test.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Treatment A

    Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).

    Drug: Oxycodone

  • Experimental
    Treatment B

    Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).

    Drug: Oxycodone

  • Experimental
    Treatment C

    Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).

    Drug: Oxycodone

  • Experimental
    Treatment D

    Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).

    Drug: Oxycodone

  • Experimental
    Treatment E

    Single dose of 5 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).

    Drug: Oxycodone

  • Experimental
    Treatment F

    Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).

    Drug: Oxycodone

Interventions

  • One capsule of 40 mg PF-00345439 Formulation A, single dose

  • One capsule of 40 mg PF-00345439 Formulation E, single dose

  • One capsule of 40 mg PF-00345439 Formulation F, single dose

  • One capsule of 40 mg PF-00345439 Formulation G, single dose

  • One capsule of 5 mg PF-00345439 Formulation TBD, single dose

  • One capsule of 40 mg PF-00345439 Formulation H, single dose

06

What researchers measure

Primary outcomes

  1. Area Under the Curve from Time Zero to Extrapolated Infinite Time [AUC(0-inf)]

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, and 48 hours post-dose.

  2. Maximum Observed Plasma Concentration (Cmax)

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, and 48 hours post-dose.

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of Oxycodone in Treatment E

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, and 48 hours post-dose.

  2. Area Under the Curve from Time Zero to Extrapolated Infinite Time [AUC(0-inf)] of Oxycodone in Treatment E

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, and 48 hours post-dose.

  3. Area Under the Curve from Time Zero to Last Quantifiable Concentration (AUClast)

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, and 48 hours post-dose.

  4. Plasma Concentration 24 Hours Post-Dose (C24)

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, and 24 hours post-dose.

  5. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, and 48 hours post-dose.

  6. Plasma Decay Half-Life (t1/2)

    Time frame: 0, 0.5, 1, 2, 4, 6, 8, 12, 14, 16, 24, 36, and 48 hours post-dose.

07

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06511, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 13, 2012
Start
Mar 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Aug 31, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01552863
Lead sponsor
Pain Therapeutics
Responsible party
Sponsor
First posted
Mar 13, 2012
Start date
Mar 2012
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Aug 31, 2015

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion